MediWound (MDWD) News Today $17.73 -0.89 (-4.76%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$17.70 -0.03 (-0.17%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg UlcersFebruary 12, 2025 | finanznachrichten.deMediWound begins pivotal Phase III trial for wound therapyFebruary 12, 2025 | msn.comMediWound stock climbs 4% on Phase 3 study initiationFebruary 12, 2025 | msn.comMediWound to launch Phase III trial for venous leg ulcersFebruary 12, 2025 | reuters.comMediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg UlcersFebruary 12, 2025 | globenewswire.comMediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | finance.yahoo.comJPMorgan Chase & Co. Sells 75,360 Shares of MediWound Ltd. (NASDAQ:MDWD)JPMorgan Chase & Co. decreased its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 95.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,401 shares of the biopharmaceuticalFebruary 4, 2025 | marketbeat.comMediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last weekJanuary 29, 2025 | finance.yahoo.comBuy Rating for Mediwound Driven by EscharEx’s Market Potential and Disruptive Role in Chronic Wound CareJanuary 11, 2025 | markets.businessinsider.comMediwound (MDWD) Receives a Buy from TD CowenJanuary 10, 2025 | markets.businessinsider.comBuy Rating for Mediwound Driven by EscharEx’s Promising Market Potential and Revenue GrowthJanuary 10, 2025 | markets.businessinsider.comMediWound (NASDAQ:MDWD) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of MediWound in a research report on Friday.January 10, 2025 | marketbeat.comState Street Corp Raises Holdings in MediWound Ltd. (NASDAQ:MDWD)State Street Corp boosted its stake in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 219.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,258 shares of the biopharmaceutical company's stock after purchasing an addiJanuary 3, 2025 | marketbeat.comMediWound (NASDAQ:MDWD) Share Price Passes Below 50-Day Moving Average - Should You Sell?MediWound (NASDAQ:MDWD) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?December 28, 2024 | marketbeat.comWe're Keeping An Eye On MediWound's (NASDAQ:MDWD) Cash Burn RateDecember 24, 2024 | finance.yahoo.comMediWound Approves 2024 Share Incentive Plan to Boost Employee EngagementDecember 19, 2024 | tipranks.comMediWound to host virtual KOL event to discuss EscharEx Phase III VALUE studyDecember 18, 2024 | markets.businessinsider.comMediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s FutureDecember 17, 2024 | markets.businessinsider.comStrategic Growth and Market Potential Drive Buy Rating for MediWound Despite Revenue DeclineDecember 6, 2024 | markets.businessinsider.comBrokers Offer Predictions for MediWound FY2024 EarningsMediWound Ltd. (NASDAQ:MDWD - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for MediWound in a research note issued on Wednesday, November 27th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earninDecember 2, 2024 | marketbeat.comMediWound (NASDAQ:MDWD) Stock, Option ChainNovember 28, 2024 | benzinga.comMediWound (NASDAQ:MDWD) Given New $25.00 Price Target at HC WainwrightHC Wainwright cut their price objective on MediWound from $28.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday.November 27, 2024 | marketbeat.comMediWound Advances Enzymatic Therapeutics Amid Financial ShiftsNovember 27, 2024 | markets.businessinsider.comMediwound’s Promising Outlook: Expansion and Trials Support Buy RatingNovember 26, 2024 | markets.businessinsider.comMediWound Ltd. (MDWD) Q3 2024 Earnings Call TranscriptNovember 26, 2024 | seekingalpha.comMediWound Reports Third Quarter 2024 Financial Results and Provides Company UpdateNovember 26, 2024 | globenewswire.comEarnings Preview: MediWoundNovember 25, 2024 | benzinga.comWhat To Expect From MediWound Ltd (MDWD) Q3 2024 EarningsNovember 25, 2024 | finance.yahoo.comMediWound (MDWD) to Release Earnings on TuesdayMediWound (NASDAQ:MDWD) will be releasing earnings before the market opens on Tuesday, November 26, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=648662)November 19, 2024 | marketbeat.comMediWound to Discuss New Share Incentive PlanNovember 14, 2024 | markets.businessinsider.comMediWound to Report Third Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comARK Investment Management LLC Invests $1.81 Million in MediWound Ltd. (NASDAQ:MDWD)ARK Investment Management LLC acquired a new stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 99,994 shares of the biopharmaceutical company'sNovember 9, 2024 | marketbeat.comRosalind Advisors Inc. Has $11.34 Million Stock Holdings in MediWound Ltd. (NASDAQ:MDWD)Rosalind Advisors Inc. grew its position in MediWound Ltd. (NASDAQ:MDWD - Free Report) by 22.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 628,050 shares of the biopharmaceutical company's stock after acquiring an additiNovember 6, 2024 | marketbeat.comMediWound Is A Healthy InvestmentOctober 29, 2024 | seekingalpha.comMediWound's (NASDAQ:MDWD) investors will be pleased with their stellar 125% return over the last yearOctober 27, 2024 | finance.yahoo.comRosalind Advisors, Inc. Increases Stake in MediWound LtdOctober 24, 2024 | uk.finance.yahoo.comMediWound (NASDAQ:MDWD) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comMediwound’s EscharEx Poised for Growth: A Comprehensive Valuation and Buy Rating Amidst Clinical StudiesOctober 11, 2024 | markets.businessinsider.comMediWound (NASDAQ:MDWD) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of MediWound in a research note on Friday.October 11, 2024 | marketbeat.comMediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg UlcersOctober 10, 2024 | globenewswire.comMediWound (NASDAQ:MDWD) Stock Passes Below 200 Day Moving Average of $16.99MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200 Day Moving Average of $16.99September 11, 2024 | marketbeat.comMediWound to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comMediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average of $18.20MediWound (NASDAQ:MDWD) Stock Crosses Above 50-Day Moving Average of $18.20September 3, 2024 | marketbeat.comMediwound Poised for Growth: Buy Rating Backed by NexoBrid Expansion and EscharEx Market PotentialAugust 22, 2024 | markets.businessinsider.comMediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutionsAugust 21, 2024 | finance.yahoo.comBrokers Set Expectations for MediWound Ltd.'s Q3 2024 Earnings (NASDAQ:MDWD)MediWound Ltd. (NASDAQ:MDWD - Free Report) - Analysts at HC Wainwright raised their Q3 2024 earnings estimates for MediWound in a research report issued on Thursday, August 15th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($0.August 19, 2024 | marketbeat.comFY2027 EPS Estimates for MediWound Ltd. Cut by HC Wainwright (NASDAQ:MDWD)MediWound Ltd. (NASDAQ:MDWD - Free Report) - Research analysts at HC Wainwright dropped their FY2027 earnings estimates for MediWound in a report issued on Thursday, August 15th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of $1.2August 16, 2024 | marketbeat.comMediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal BurnsAugust 15, 2024 | globenewswire.comBuy Rating Justified by MediWound’s Strong Financials and Product Expansion PotentialAugust 15, 2024 | markets.businessinsider.comMediWound (NASDAQ:MDWD) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $28.00 price target on shares of MediWound in a research note on Thursday.August 15, 2024 | marketbeat.com Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address MDWD Media Mentions By Week MDWD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDWD News Sentiment▼0.000.60▲Average Medical News Sentiment MDWD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDWD Articles This Week▼01▲MDWD Articles Average Week Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avid Bioservices News Nuvation Bio News Prothena News Cronos Group News GH Research News Bicara Therapeutics News Verve Therapeutics News Mind Medicine (MindMed) News Dianthus Therapeutics News Anavex Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDWD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDWD Stock Alerts